Member Info for Uncanny

Ambrose Healthcare | 2025 Highlights and What’s Ahead in 2026

Dear Colleague / Partner,

As we begin 2026, we would like to share a brief reflection on the past year at Ambrose Healthcare and outline what lies ahead in delivering its mission, to bring new therapeutics to rare disease patients who currently have no approved drug treatment.

Our last update was shared in October 2025. Since then, meaningful progress has been made across our programmes, partnerships, and team, all in support of our mission to bring treatments to patients living with rare and underserved conditions.

2025 at a Glance

During 2025, Ambrose focused on building strong scientific, operational, and partnership foundations to support the next phase of development:

Continued preparation for the Renzapride Phase 2 trial for the treatment of the Gastrointestinal Manifestations of Cystic Fibrosis (GMCF), including regulatory planning and UK clinical engagement

Exercised the licensing option for VAL401, securing global rights for development and commercialisation for treatment of cancers. 20% of cancers are classified as rare diseases. Ambrose is focusing initially on development for the treatment of pancreatic cancer

Strengthened leadership, governance, and delivery capability

Expanded engagement with clinicians, researchers, and funding partners across the UK and internationally

Much of this work took place behind the scenes, laying the groundwork for accelerated progress in 2026.

Scientific Leadership

We are pleased to be working closely with Professor Bu Hayee, Kings Hospital, London who oversees the GMCF treatment centre for the Southeast of England and is supporting Ambrose as a Scientific Advisor for development of Renzapride for GMCF, providing valuable clinical insight as the programme progresses.

We were deeply saddened by the passing of Professor Brian Feagan during 2025. Professor Feagan was internationally respected for his leadership in clinical trial design and execution. His early engagement with Ambrose and belief in rigorous, patient-centred development left a lasting impact on our work and thinking.

Looking Ahead to 2026

In the year ahead, Ambrose Healthcare will focus on disciplined execution and collaboration, with priorities including:

Advancing Renzapride toward initiating its Phase 2 study

Preparing VAL401 for Phase 2 clinical development

Pursuing investment as well as public and charitable grant funding, including a recent formal invitation to submit a major UK grant application for Renzapride

Continuing to build trusted partnerships with clinicians, academic groups, and research organisations

These activities reflect Ambrose’s commitment to capital-efficient development and strong alignment with the UK life sciences ecosystem.

Planning Named Patient Supply

We are also planning to initiate Named Patient Supply (NPS) activities.

Named Patient Supply enables access to Good Manufacturing Practice-manufac

Bubbling up nicely 👍

‘Blithering idiot’…. thanks Porky 😂

Jury still out TBH

Still have a nice chunky eight figure Holding so obviously happy, but not sure if this has been driven by traders in which case profit-taking will happen, or whether it is holders in which case the price will consolidate.

GLA NAI DYOR

Are we heading sub .30 or just a blip?

Have a wonderful Xmas break everyone!

Best wishes

S.

TBH I thought the update was excellent and you can see all the areas where ME is pushing on to monetise the assets plus the fact that the cash burn has reduced so significantly and now there is a clear runway up to H2 2026 is excellent.

It’s also appears and obviously he couldn’t say in the presentation, that there are probably quite a few surprises in the next six months to which will help in terms of inflection points that will probably push this price way beyond the 0.5p warrant exercise but probably up to the 1p mark or perhaps even further who knows!

NAI DYOR GLA

Saying that, sellers now appearing 🤨

Well no pumping or dumping today, so we have a stale mate!

Well Ice I wish you the best of luck as well mate as we all deserve it, but in terms of my buyback. Have a look at the one on the 16th of December which incidentally was my birthday buying 4 million shares at .33 timed at 1632.

👍😉

Notpotalot

😂😂😂

I actually sold a 50% at .38 and bought back almost everything at .33, except I have kept just below the 3% TR1 level as opposed to 3.25% (and Reportable ) as previously so I have more flexibility.

Sadly unable to partake in the placing, I went from 6% down to just over 3% which was a bitter pill to swallow, but of course I know the risks so if I can make a few pounds here and there then happy days although I wouldn’t call myself a trader by any stretch of the imagination as I am a long-term holder and have been since 2019.

I do think that news will be good during 2026 as a holder, but in the short term, I think we will witness gyrations as people are trading the peaks and troughs day-to-day at the moment and this is just moving on speculation and hot air as we’ve had no news flow, albeit I am adamant that this will come in the next months to come. 👍

Just FYI.

GLA DYOR NAI

I can see the traders walking this down now as they take their profits off the table.

I think 2026 will be our time!

GLA DYOR NAI

Hi ice

Yes, I’m just a tad below 3% 👍

UXM, Zak says it keeps rebounding back from 50 RSI, will it rebound again to lower 30’s again or not is the $64,000 question?

Well we shall see lceman as this is the fourth time this little rally has happened at this level (mid 30’s) as the last three times it’s just fizzled out back to the low 30’s so I agree we need news as the trading is not sustainable on its own to move out of this price range IMHO.

Time will tell 👍

Oh chaps, that is very sweet.

Well, probably gonna have another bout of profit taking again as we get to 36p mid for the 4th time, in fact if you look at the chart from the 2nd of December, the Lows seem to be getting lower.

NAI DYOR GLA

Some big sells there at the end l think?

UXM484…… that’s where layeth the problem as you say:

“You do realise your entire holding will be wiped out if the warrants do not get exercised in the coming months.“

Basically need news or this will justly keep gyrating 32p to 38p and back down to 32p which l think is three times now.

Great for traders but not for longs.

PP- “Rumour has it, you reduced your holding expecting the SP to tumble following the TR1 and are now working to get back towards your original holding.”

There are only two people that l know, know my intentions either way and if it has been divulged then they have lost my trust sadly and l might have to think of my options unfortunately going forwards.